Cargando…
Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis
The purpose of this work was to review and synthesise the evidence on the comparative effectiveness of neutralising monoclonal antibody (nMAB) therapies in individuals exposed to or infected with SARS-CoV-2 and at high risk of developing severe COVID-19. Outcomes of interest were mortality, healthca...
Autores principales: | McConnell, David, Harte, Marie, Walsh, Cathal, Murphy, Desmond, Nichol, Alistair, Barry, Michael, Adams, Roisin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583057/ https://www.ncbi.nlm.nih.gov/pubmed/36266486 http://dx.doi.org/10.1038/s41598-022-22431-6 |
Ejemplares similares
-
Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
por: Berry, Jody D, et al.
Publicado: (2004) -
Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2
por: McConnell, David, et al.
Publicado: (2021) -
Clinical utility of anti-interleukin 5 monoclonal therapy in asthma using a national, centralised, outcome-based system of drug access
por: O'Leary, Caroline, et al.
Publicado: (2022) -
Humanised monoclonal antibodies neutralise pertussis toxin by receptor blockade and reduced retrograde trafficking
por: Acquaye‐Seedah, Edith, et al.
Publicado: (2018) -
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)